ZA200810834B - Long term 24 hour intestinal administration of levodopa/carbidopa - Google Patents

Long term 24 hour intestinal administration of levodopa/carbidopa

Info

Publication number
ZA200810834B
ZA200810834B ZA200810834A ZA200810834A ZA200810834B ZA 200810834 B ZA200810834 B ZA 200810834B ZA 200810834 A ZA200810834 A ZA 200810834A ZA 200810834 A ZA200810834 A ZA 200810834A ZA 200810834 B ZA200810834 B ZA 200810834B
Authority
ZA
South Africa
Prior art keywords
carbidopa
levodopa
long term
intestinal administration
hour
Prior art date
Application number
ZA200810834A
Other languages
English (en)
Inventor
Dag Nyholm
Stefan Asberg
Roger Bolsoey
Mikael Tutschke-Saettler
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of ZA200810834B publication Critical patent/ZA200810834B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA200810834A 2006-05-31 2007-05-31 Long term 24 hour intestinal administration of levodopa/carbidopa ZA200810834B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80988906P 2006-05-31 2006-05-31

Publications (1)

Publication Number Publication Date
ZA200810834B true ZA200810834B (en) 2010-03-31

Family

ID=38434843

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200810834A ZA200810834B (en) 2006-05-31 2007-05-31 Long term 24 hour intestinal administration of levodopa/carbidopa

Country Status (16)

Country Link
US (1) US20080051459A1 (ko)
EP (1) EP2063865A1 (ko)
JP (1) JP2009543761A (ko)
KR (1) KR20090057349A (ko)
CN (1) CN101636145B (ko)
AU (1) AU2007267135B2 (ko)
BR (1) BRPI0711882A2 (ko)
CA (1) CA2653683A1 (ko)
HK (1) HK1137931A1 (ko)
IL (1) IL195599A0 (ko)
MX (1) MX2008015339A (ko)
NO (1) NO20085418L (ko)
RU (1) RU2484815C2 (ko)
UA (1) UA95954C2 (ko)
WO (1) WO2007138086A1 (ko)
ZA (1) ZA200810834B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5466179B2 (ja) * 2008-02-06 2014-04-09 ウォックハート リサーチ センター 生物学的利用能が改善されたエンタカポン、レボドパ及びカルビドパの医薬組成物
MX364974B (es) * 2009-05-19 2019-05-16 Neuroderm Ltd Composiciones para la administracion continua de inhibidores de dopa descarboxilasa.
WO2012066538A1 (en) 2010-11-15 2012-05-24 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
EP2653179B1 (en) 2012-04-17 2019-07-10 Micrel Medical Devices S.A. System for calculating and administering a drug to a patient with Parkinson's disease
EP3456315A1 (en) 2012-06-05 2019-03-20 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
RS65060B1 (sr) 2014-03-13 2024-02-29 Neuroderm Ltd Sastavi inhibitora dopa dekarboksilaze
JP6622310B2 (ja) 2014-09-04 2019-12-18 ロブソル・ファーマシューティカルズ・アクチボラグＬｏｂｓｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｂｏｌａｇ レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法
AU2015335941B2 (en) * 2014-10-21 2021-04-01 Abbvie Inc. Carbidopa and L-dopa prodrugs and their use to treat Parkinson's disease
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
WO2016179540A1 (en) 2015-05-06 2016-11-10 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
JP2019523249A (ja) * 2016-07-20 2019-08-22 アッヴィ・インコーポレイテッド レボドパ及びカルビドパ腸管ゲル、並びに使用方法
WO2018034626A1 (en) 2016-08-18 2018-02-22 İlko İlaç Sanayi Ve Ticaret Anonim Şirketi Antiparkinson tablet formulation with improved dissolution profile
US11844860B2 (en) 2018-03-02 2023-12-19 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
WO2019182506A1 (en) 2018-03-23 2019-09-26 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
WO2019191353A1 (en) * 2018-03-29 2019-10-03 Riverside Pharmaceuticals Corporation Levodopa fractionated dose composition and use
US11389398B2 (en) 2019-05-14 2022-07-19 Clexio Biosciences Ltd. Gastroretentive treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
WO2023126945A1 (en) * 2022-01-03 2023-07-06 Neuroderm, Ltd. Methods and compositions for treating parkinson's disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
EA200300046A1 (ru) * 2000-06-23 2003-10-30 Тева Фармасьютикал Индастриес Лтд. Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
AU2004285436C1 (en) * 2003-10-20 2009-07-16 Teva Pharmaceutical Industries Ltd. Composition and dosage form for sustained effect of levodopa
NZ551511A (en) * 2004-06-04 2010-09-30 Xenoport Inc Levodopa prodrugs, and compositions and uses thereof
WO2006044202A2 (en) * 2004-10-19 2006-04-27 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions

Also Published As

Publication number Publication date
CN101636145A (zh) 2010-01-27
BRPI0711882A2 (pt) 2012-01-10
AU2007267135B2 (en) 2013-03-07
JP2009543761A (ja) 2009-12-10
RU2008150776A (ru) 2010-07-10
US20080051459A1 (en) 2008-02-28
EP2063865A1 (en) 2009-06-03
UA95954C2 (ru) 2011-09-26
HK1137931A1 (en) 2010-08-13
MX2008015339A (es) 2008-12-16
CN101636145B (zh) 2014-04-23
AU2007267135A1 (en) 2007-12-06
RU2484815C2 (ru) 2013-06-20
WO2007138086A1 (en) 2007-12-06
IL195599A0 (en) 2009-09-01
NO20085418L (no) 2009-02-26
CA2653683A1 (en) 2007-12-06
KR20090057349A (ko) 2009-06-05

Similar Documents

Publication Publication Date Title
HK1137931A1 (en) Long term 24 hour intestinal administration of levodopa/carbidopa 24 /
IL175314A0 (en) Administration of levodopa and carbidopa
IL186684A0 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
EP1987068A4 (en) MODIFICATION OF OLIGOSACCHARIDES AND MARKING OF PROTEINS
EP2104424A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
EP1924318A4 (en) SYNCHRONIZATION OF REPETITIVE THERAPEUTIC INTERVENTIONS
GB0604535D0 (en) Betulonic acid derivatives
HK1128477A1 (zh) 甘草次酸衍生物
PL1994004T3 (pl) 1,4-Dipodstawione pochodne 3-cyjano-pirydonu i ich zastosowanie jako pozytywnych allosterycznych modulatorów receptorów MGLUR2
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINS
IL193473A0 (en) Amide derivatives and their application for the treatment of g protein related diseases
HK1111347A1 (zh) 左旋多巴輸液和注射液
GB2436421B (en) Timing source
WO2011044230A9 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
HRP20130544T1 (en) Long term treatment of hiv- infection with tcm278
GB0622834D0 (en) Timing source
IL198513A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
IL194189A0 (en) Combination treatment of metabolic disorders
IL193687A0 (en) Formulations of sitaxsentan sodium
ZA200800348B (en) Derivatives of seleno-amino acids
GB0602780D0 (en) Amino Acid Derivatives
TWI372762B (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
IL187732A0 (en) Levodopa compositions
GB0601688D0 (en) Cuff fasteners